MedTrace Logo

Induction of Stable Chimerism for Sickle Cell Anemia

NCT00029393 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-07-29

No results posted yet for this study

Summary

To investigate a modified hematopoeitic cell transplantation (HCT) procedure for sickle cell disease that significantly reduces the toxicity of HCT, yet retains its therapeutic benefit.

Conditions

  • Blood Disease
  • Hematopoietic Stem Cell Transplantation
  • Anemia, Sickle Cell

Interventions

PROCEDURE

Hematopoietic Stem Cell Transplantation

DRUG

Immunosuppression

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Mark Walters · UCSF Benioff Children's Hospital Oakland

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-31
Primary Completion
2007-07-31
Completion
2007-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00029393 on ClinicalTrials.gov